Skip to main content

Anti-Cancer Drug Design is now published as Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.

Publisher: Cognizant Communication Corporation

Volume 12, Number 8, 1997

Geiparvarin and derivatives in combination with taxol: effect on microtubular organization in 3T3 fibroblasts
pp. 607-620(14)
Authors: Miglietta, A; Bocca, C; Rampa, A; Bisi, A; Gabriel, L


Dimethylsilane polyamines: cytostatic compounds with potentials as anticancer drugs
pp. 621-633(13)
Authors: Douaud, F; Le Roch, N; Renault, J; Havouis, R; Vaultier, M; Moulinoux, J-P; Seiler, N


Molecular modelling and biological evaluation of a series of hydroxylated benzylideneanilines and benzylamines designed as tyrosine kinase inhibitors
pp. 635-647(13)
Authors: Solomons, KRH; Lieberman, HF; Groundwater, PW; Hibbs, DE; Hursthouse, MB


P1GT-saporin fusion protein: a potential anti-angiogenic agent
pp. 649-657(9)
Authors: Chiaramonte, R; Polizzi, D; Bartolini, E; Petroni, D; Comi, P


Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs
pp. 659-670(12)
Authors: Kunkel, MW; Kirkpatrick, DL; Johnson, JI; Powis, G


Cytotoxicity and subcellular localization of boronated phenanthridinium analogues
pp. 671-685(15)
Authors: Gedda, L; Silvander, M; Sjöberg, S; Tjarks, W; Carlsson, J


The complete issue is available for purchase


Purchasing this issue will give you access to all of the articles listed above for 2 days. You may also purchase articles individually by visiting the abstract page of the article. The exact price (including tax) will be displayed in your shopping cart before you check out. You will be able to remove this item from your shopping cart at any time before you have completed check-out.

Add to cart

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more